The drug, Strattera® (atomoxetine), will provide treatment for children between the ages of six and 18 years who cannot take stimulants.
ADHD is a behavioural and developmental disorder that affect young children. The main symptoms of ADHD – inattention, hyperactivity and impulsivity – contribute to adverse academic and social behaviour, which can have consequences that persist throughout adolescence and into adulthood.
Treatment for ADHD normally involves stimulant therapy, so the listing of Strattera® on the PBS will especially benefit those who are unable to take stimulants.
About 18,000 people will commence Strattera® in the first full financial year of listing.
The listing of Strattera® will add around $101.2 million to PBS and Repatriation Pharmaceutical Benefits Scheme expenditure between 2007-08 and 2010-11.